ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether treatment with a new drug called
ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate
cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA
(Prostate-specific antigen) levels.